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Abstract 
BACKGROUND: The rapidly growing knowledge regarding factors controlling tumour growth, with the new 
modalities of therapy acting on the biological activity of the tumours draw the attention of most cancer researches 
nowadays and represent a major focus for clinical oncology practice. For the detection of HER2/neu protein 
overexpression and gene amplification, immunohistochemistry (IHC) and in-situ hybridisation (ISH) is the 
recommended techniques, respectively, with high concordance between the two techniques. The current United 
Kingdom recommendations for HER2/neu testing are either for a two-tier system using IHC with reflex ISH testing 
in equivocal positive cases, or a one-tier ISH strategy.  
AIM: To compare the results of HER2/neu gene status in patients with breast carcinoma obtained by chromogenic 
in situ hybridisation with those obtained by immunohistochemistry, and to compare these results with hormonal 
receptors expression by immunohistochemistry and with age of patients. 
METHODS: Immunohistochemistry technique was used for evaluation of status of estrogen receptors (ER) and 
progesterone receptors (PR) and HER2/neu protein expression in 448 Iraqi patients with invasive breast 
carcinoma with different grades and histological types and then chromogenic in situ hybridization (CISH) 
technique was applied for all scores of HER2/neu to detect the gene status and compare the results in all 
negative, equivocal and positive cases by immunohistochemistry (IHC). The cases were referred from different 
centres, and IHC and CISH techniques were done in central public health laboratory in Baghdad over 28 months, 
from July 2013 to November 2015. A comparison of the results was made to find the relationship between 
HER2/neu and hormone receptors status and other clinical parameters like patients age.  
RESULTS: The mean age of the study cases was 49.08 years, ranging from 24 to 83 years. Of the 448 cases of 
breast carcinoma, 44 (9.8%) cases were of score 0 by IHC, none of them (0%) showed HER2/neu gene 
amplification by CISH. 71(15.8%) cases were of score 1 by IHC, 15 (21.12%) of them showed HER2/neu gene 
amplification by CISH, all were of low amplification. There were 306 (68.3%) cases of score 2 by IHC, of which 
102 (33.33%) cases showed HER2/neu gene amplification by CISH, with 79 (25.81%) of them with low 
amplification and 23 (7.51%) cases with high amplification, while only one case (0.32%) remained in equivocal 
category. In score 3, all the 27 (6.0%) cases showed gene amplification with 12 (44.44%) cases with low 
amplification and 15 (55.55) cases with high amplification with overall percentage of gene amplification in score 3 
of 100%. There was a significant inverse relationship between hormone receptors (ER and PR) status and 
HER2/neu gene amplification. No significant relationship was found between the patient’s age and HER2/neu 
gene amplification. 
CONCLUSION: Although immunohistochemistry is a widely used, less expensive and reliable test, we strongly 
advice performance of chromogenic in situ hybridization in assessment of HER2/neu gene status in all cases 
diagnosed with breast carcinoma as significant number of cases that were reported as negative by 
immunohistochemistry showed positive amplification by chromogenic in situ hybridization and can get benefit from 
anti-HER2 targeted treatments. 
 
Introduction 
 
ERBB2 (HER2/neu), a human epidermal 
growth factor receptor, is a member of the tyrosine 
kinases family that is involved in important signalling 
pathways controlling cell proliferation and tumour 
growth and survival [1]. Hyperfunction of this receptor, 
due to gene amplification and protein overexpression, 
has been reported and evaluated in different types of 
cancers
 
[2]. In approximately 15% of early invasive 
breast carcinoma, ERBB2 (HER2/neu) 
overexpression is present and serve as a poor 
prognostic marker and an important predictive of 
response to specific therapy [3].
 
Tumours with 
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increased levels of the ERBB2 (HER2/neu) are 
characterised by more aggressive histological 
features, more rapid growth rate and a shortened 
overall survival and relapse-free time, compared with 
those with no ERBB2 (HER2/neu) overexpression [4]. 
The great response achieved with anti-
ERBB2 (HER2/neu) targeted therapies in ERBB2 
(HER2/neu)-positive breast carcinoma cases in 
addition to serious side effects of these expensive 
drugs increase the necessity for accurate assessment 
of ERBB2 (HER2/neu) status [3]. 
Also, other studies stated that cases with 
overexpression of ERBB2 (HER2/neu) are associated 
with impaired responsiveness to tamoxifen (anti-
estrogen targeted treatment) in breast carcinoma that 
is positive for both ERBB2 (HER2/neu) and hormone-
receptor
 
[5]. 
The rapid development of new, clinically 
advanced information in this subject can induce 
challenges for oncologists to understand and properly 
react to these updates [3].
 
ERBB2 (HER2/neu) status should be 
determined in all newly diagnosed, recurrent and 
metastatic breast carcinoma. Bilateral tumours, 
histologically different ipsilateral tumours or widely 
separated tumours should each be assessed. 
Retesting the non-responding stable or progressive 
ERBB2 (HER2/neu)-negative tumours particularly the 
high-grade or those with a long interval time between 
preoperative biopsy and excisional surgery may be 
considered but are not recommended routinely 
because of the lack of evidence [3].
 
By immunohistochemistry, more than 10% 
complete strong membrane staining defines a positive 
status of protein overexpression. In situ hybridisation, 
either bright field chromogenic or fluorescent is used 
either initially or in immunohistochemistry equivocal 
positive cases to detect the presence of ERBB2 
(HER2/neu) gene amplification [3]. 
Excellent concordance in results between 
needle core biopsy and surgical specimens has been 
obtained using immunohistochemistry (IHC) and in 
situ hybridisation (ISH) [6]. In most centers in United 
Kingdom, ERBB2 (HER2/neu) testing is performed on 
diagnostic core biopsy specimens, mainly for the 
results to be available at the time of postoperative 
multidisciplinary team (MDT) for treatment plan 
discussion and also to study the use of neoadjuvant 
treatment which is increasingly given for operable 
cases with no repeat on excision specimens needed if 
the test is strongly positive or negative. However; re-
performing the assay on incisional or excisional 
surgical specimens can be considered in the following 
conditions: 
- When the initial ERBB2 (HER2/neu) test 
result in a core needle biopsy specimen of a primary 
breast carcinoma is negative, another ERBB2 
(HER2/neu) test could be ordered on the excisional 
specimen if the tumor grade is 3, if small amount of 
invasive carcinoma is present in the core biopsy 
specimen, if resection specimen contains carcinoma 
of higher grade than that in the core, if results of core 
biopsy is equivocal for ERBB2 (HER2/neu) by both 
ISH and IHC, or if there is any doubt about handling of 
the core biopsy specimen (short fixation time, long 
ischemic time, different fixatives). 
- When the initial ERBB2 (HER2/neu) test 
result in a core needle biopsy specimen of a primary 
breast carcinoma is positive, another ERBB2 
(HER2/neu) test could be ordered on the excisional 
specimen in histologic grade 1 carcinoma of the 
following types: ER and PR positive infiltrative ductal 
or lobular carcinoma, tubular, mucinous, cribriform or 
adenoid cystic carcinoma. While a new ERBB2 
(HER2/neu) test must not be done in previous 
histologic types if the initial ERBB2 (HER2/neu) test 
was negative [6], [7]. 
Cytology specimens from fine needle 
aspiration of primary breast carcinoma are not ideal 
for assessment of ERBB2 (HER2/neu) status by IHC 
as that differentiation between invasive and in situ 
carcinoma cannot be made on these samples. 
However, if the cytology specimens are the only 
available material, or in case of metastasis, some 
studies indicate that ISH is reliable for assessment of 
ERBB2 (HER2/neu) status in liquid-based and cell 
block preparations [8]. 
In the case of bone metastasis, when ERBB2 
(HER2/neu) assessment is required, decalcification 
techniques can detrimentally affect 
immunohistochemical assessment, and these 
decalcified specimens should be better tested with 
ISH techniques
 
[9], [10]. 
 
Algorithms to be followed for testing 
 ERBB2 (HER2/neu) 
For determination of ERBB2 (HER2/neu) 
status, IHC for evaluation of protein overexpression 
and ISH for assessment of gene amplification status 
are the recommended techniques. High agreement 
between protein overexpression and gene 
amplification is reported [4], [11], [12]. The current 
recommendations in the United Kingdom for ERBB2 
(HER2/neu) testing are for “a two-tier system using 
IHC with reflex ISH testing if required, using the model 
shown in figure 1, or a one-tier ISH strategy”. In the 
usual practice for ERBB2 (HER2/neu) testing IHC is 
used with the analysis of equivocal positive cases by 
ISH; however, some laboratories use upfront ERBB2 
(HER2/neu) ISH testing, especially if the quality of 
tissue fixation and processing is questionable [13]. 
ISH has usually been performed using a 
fluorescence ISH (FISH) technique. Bright-field ISH 
can be used to assess ERBB2 (HER2/neu) status with 
a light microscope and is now considered as an 
acceptable alternative to FISH [14].  
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Figure 1: Recommended ERBB2 (HER2/neu) scoring algorithm for 
immunohistochemistry (IHC) and in situ hybridisation (ISH); *no 
sufficient data is available about moderate complete membrane 
staining in ≤ 10% of tumour cells or strong incomplete membrane 
staining in > 10% of tumour cells. Repeat on another specimen 
(tissue block) is advisable; **Membrane staining should be intense 
and uniform and like chicken-wire. Ignoring incomplete and pale 
membrane staining in percentage estimation 
 
The most widely used bright field ISH uses a 
DNA probe coupled to a silver ISH or chromogenic 
ISH detection system, or a combination of both [14]. 
ISH can be performed using either a single probe to 
enumerate ERBB2 (HER2/neu) copies per nucleus or 
a dual-probe technique that allows determination of 
the ERBB2 (HER2/neu): CEP17 ratio and ERBB2 
(HER2/neu) gene copy number. Because of this, the 
use of a chromosome 17 probe is strongly advocated 
[3]. 
IHC is a semi-quantitative method for analysis 
of HER2/neu protein expression, and it is quick, easy 
and less expensive; however, it is more subjective 
and susceptible to discrepancies in test results with 
different laboratory parameters [15]. ISH is a 
quantitative method for analysis of HER2/neu gene 
copy number; however, it is more time consuming and 
costly but more reliable because of its quantitative 
nature [16], [17]. The choice of most suitable test for 
HER2/neu status is still an area of discussion with 
various studies showing and evaluating different 
opinions regarding the gold standard test algorithm to 
be followed [18]. 
 
Chromogenic in situ hybridisation (CISH) 
CISH assays depend on a technique named 
subtractive hybridisation that uses a DNA probe 
visualised by a peroxidase reaction. CISH is a new 
technique that uses a chromogen-labelled probe 
which offers several advantages. First, simultaneous 
assessment of tissue morphology and CISH signals at 
high power using a light microscope. Second, by 
using the dual probe method, two targets can be 
detected at the same time. Third, high contrasting 
between distinct red and green signals. Fourth, it 
allows quick and easy interpretation of results as 
compared to IHC, and it is standardised with complete 
kits and no need for costly fluorescent microscope 
[19]. 
Fixation and processing of the specimens 
 for HER2/neu assessment 
Proper fixation of specimens used for 
HER2/neu testing must be ensured and the cold 
ischemic time (the time between removal of the tissue 
from the patient and its placing in fixative) should be 
as short as possible, typically less than one hour [20]. 
Formalin-fixed, paraffin-embedded tumour tissue 
samples are suitable for the assay. Tumour samples 
must be fixed in buffered formalin and embedded in 
paraffin wax; fixatives that contain alcohol will result in 
staining of normal tissue and the use of Bouin’s 
fixative will prevent testing by fluorescence in situ-
based methods. Other methods of fixation can also 
badly affect antigen reactivity [3].  
 At least six hours of fixation are 
recommended for the core biopsies. Surgical 
specimens have to be incised as near as possible 
through the carcinoma to allow good penetration of 
the fixative and then dissected into 5 – 10 mm slices 
to ensure rapid penetration and fixation. Tissue must 
be placed in an adequate volume (typically 1:10; 
tissue: fixative) of fixative for at least twenty-four hours 
and not more than three days. Centres that use rapid 
fixation and processing methods should validate their 
methodology for HER2/neu assessment [3]. 
 Sections must be stained within one to two 
days of cutting and drying. Excessive section drying 
time will lead to loss of HER2/neu expression, and 
therefore, it is recommended that freshly cut sections 
are either dried at 60°C for one hour or 37°C overnight 
[21].
 
 
 
 
Material and Methods 
 
Immunohistochemistry technique was used 
for evaluation of ER, PR status and HER2/neu protein 
expression in 448 Iraqi patients with invasive breast 
carcinoma with different grades and histological types 
and then CISH technique was applied for all scores of 
HER2/neu to detect the gene status and compare the 
results with all 115 (25.6%) negative, 306 (68.3%) 
equivocal and 27 (6.0%) positive cases by 
immunohistochemistry. The cases were referred from 
different centres, and IHC and CISH techniques were 
done in central public health laboratory in Baghdad 
over three years, from July 2013 to November 2015. A 
comparison of the results was made to find the 
relationship between HER2/neu and hormone 
receptors status and other clinical parameters like 
patients age. IHC test kit was provided by (Dako, 
Glostrup, Denmark) and the CISH test kit was 
provided by Zytovision medical company, ZytoDot ® 
2C SPEC ERBB2/CEN 17 Probe. 
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IHC for ER, PR and HER 2 
Multiple sections of (3-4 μm) thickness were 
cut from breast carcinoma tissue blocks and placed 
on positively charged slides to overnight incubation at 
56ºC. Sections were de-paraffinized via xylene and 
further rehydrated with graded alcohols to distilled 
water. After blocking endogenous peroxidase activity 
with 3% hydrogen peroxide in methanol, antigen 
retrieval was achieved through heating the slides in 10 
mmol/l citrate buffer (pH 6) by using a water bath. 
Rabbit monoclonal anti-HER-2/neu primary antibody 
(Dako, Glostrup, Denmark) were applied for 60 
minutes at dilution of 1:800. The Envision Kit (Dako) 
was used for the application of the secondary 
antibody. Signals were developed with 
Diaminobenzidine (DAB) followed by light nuclear 
counterstaining by haematoxylin. Each test was run 
with a known positive and negative control.  
For evaluating the immunohistochemistry for 
the ERBB2 antibody, ASCO/CAP guidelines [6]. Were 
followed, as shown in Table 1. 
Table 1: Interpretation of results of immunohistochemistry for 
the ERBB2 antibody 
Staining pattern Score HER2/neu protein 
overexpression assessment 
No membrane staining or incomplete 
membrane staining in < 10% of the invasive 
tumour cells 
0 Negative 
A weak to moderate complete membrane 
staining is observed in > 10% of tumour cells 
OR strong complete membrane staining in 
≤10% of tumour cells 
1+ Negative 
A weak to moderate complete membrane 
staining is observed in > 10% of tumour cells 
OR strong complete membrane staining in 
≤10% of tumour cells 
2+ Weakly positive/equivocal 
A strong (intense and uniform) and complete 
membrane staining in > 10% of invasive 
tumour cells 
3+ Strong positive 
 
For estrogen and progesterone receptor 
detection, Heat Induced Epitope Retrieval (HIER) was 
achieved through heating the slides in EDTA buffer 
(pH 9) for 25 minutes at 95ºC. Primary antibody 
clones used for ER and PR were DAKO 1D5 (1:200) 
and DAKO PR 88 (1:200) respectively.  
Table 2: Allred system of scoring for estrogen and 
progesterone receptors
 
Score Intensity of staining 
0 Negative 
1 Weak 
2 Intermediate 
3 Strong 
Score Percentage of stained cells 
0 No cells are ER/PR positive 
1 < 1% cells are ER/PR positive 
2 1-10% of cells are ER/PR positive 
3 11-33% of cells are ER/PR positive 
4 34-66% of cells are ER/PR positive 
5 67-100% of cells are ER/PR positive 
Allred score (intensity + percentage) Effect of hormone therapy 
0-1 No effect 
2-3 Small (20%) chance of benefit 
4-6 Moderate (50%) chance of benefit 
7-8 Good (75%) chance of benefit 
 
Interpretation of results was made as per 
ER/PR reporting guidelines of the Allred scoring 
system depending on the proportion of stained cell 
(PS), given score of 0-5 , and intensity of staining (IS), 
given score of 0-3, in a combined score (AS), from 0/8 
to 8/8, results from their summation as shown in table 
2 [21]. Proper controls were used as indicated. 
 
CISH HER2/neu 
The ZytoDot ® 2C SPEC ERBB2/CEN 17 
probe was designed for the simultaneous detection of 
ERBB2 and centromere 17 in formalin-fixed, paraffin-
embedded tissue sections or cell samples. 
 
Probe Description 
The ZytoDot® 2C SPEC ERBB2/CEN 17 
probe is a mixture of a Digoxigenin-labeled probe 
specific for the ERBB2 gene at 17q12 and a 
Dinitrophenyl-labeled CEN 17 probe specific for the 
alpha satellite centromeric region of chromosome 17 
(D17Z1). Using the ZytoDot® 2C SPEC ERBB2/CEN 
17 Probe Kit, two green (ERBB2) and two red (CEN 
17) signals are expected in a normal interphase 
nucleus. In a cell with amplification of the ERBB2 
gene locus, multiple copies of the green signal or 
green signal clusters will be observed. The results 
interpretation followed the manufacturer instructions of 
ZytoDot 2C SPEC HER2/CEN 17 Probe Kit. 
The UK recommendation when using dual 
probe CISH is to report the HER2/CEP17 signal ratio 
and HER2/neu copy number [3]. 
Tumours with a HER2/CEP17 signal ratio ≥ 
2.0 and/or a mean HER2/neu gene, copy number ≥ 6 
are said to be positive. Cases with a HER2/CEP17 
signal ratio < 2.0 with an average HER2/neu copy 
number < 4.0 signals/cells are said to be negative. 
The controversy is still present about cases with HER-
2/neu gene copy number ≥ 6, but the HER2/CEP17 
ratio is < 2 [6]. Selection and assessment of normal 
breast tissue cells to confirm proper hybridisation, 
successful detection and visualisation, before testing 
of the invasive carcinoma were done. The numbers of 
HER2/neu and chromosome 17 signals were scored 
and recorded, and the mean HER2/neu to 
chromosome 17 copy ratio is assessed in 20 – 60 
cells, where possible, using at least three distinct 
tumour fields. In cases where either obvious 
amplification is observed, or the ratio is below 1.5, 
scoring of just 20 tumour cells is sufficient.  
Cells to be assessed and scored are only 
those with identifiable nuclear borders. Over-
damaged, digested, or truncated nuclei were 
excluded. Only cells with minimum one copy of 
HER2/neu and CEP17 were scored. In cases with 
tumour heterogeneity (coexistence of different 
population of tumour cells having distinct HER2/neu 
ampliﬁcation patterns within the same tumour), or the 
ratio is close to 2.0, or the average copy number is 
between ≥ 4.0 and < 6.0 signals/cell, additional cells 
were scored (at least 40). 
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Table 3: Evaluation of HER2/neu gene status using 
chromogenic in situ hybridisation 
Amplification Her-2/neu gene status 
High-level > 10 copies or large cluster of amplicon per nucleus in > 
50% of cancer cells 
Low-level 6–10 copies or small cluster of amplicon per nucleus in > 
50% of cancer cells 
None 1–5 copies per nucleus of cancer cells 
 
 
 
Results  
 
Patients’ age 
The mean age of the 448 cases of invasive 
breast carcinoma studied in this study was 49.08 
years, ranging from 24 to 83 years old. 
 
Estrogen and Progesterone receptors 
 status by IHC 
Expression of estrogen receptors was seen in 
279 (62.27%) cases. 66 (14.7%) were with weak 
expression (AS score 2-3), 143 (31.9%) were with 
moderate expression (AS score 4-6) and 70 (15.6%) 
with strong expression (AS score 7-8). Expression of 
progesterone receptors was seen in 304 (67.85%) 
cases. Forty-nine (10.9%) were with weak expression 
(AS score 2-3), 151 (33.7) were with moderate 
expression (AS score 4-6) and 104 (23.2%) with 
strong expression (AS score 7-8). As in Table 4. 
Table 4: Estrogen and Progesterone receptors status by IHC 
Hormone 
receptors 
expression 
NO expression 
(AS score 0-1) 
Weak expression 
(AS score 2-3) 
Moderate 
expression 
(AS score 4-6) 
Strong 
expression 
(AS score 7-8) 
ER status 169 (37.7%) 66 (14.7%) 143 (31.9%) 70 (15.6%) 
PR status 144 (32.1%) 49 (10.9%) 151 (33.7) 104 (23.2%) 
 
HER2/neu protein overexpression by IHC 
HER2/neu protein overexpression was 
positive (score + 3) in 27 (6.0%) cases, equivocally 
positive (score + 2) in 306 (68.3%) cases and 
negative (score + 1/0) in 115 (25.6%) cases of the 
studied specimens. As in Table 5. 
Table 5: HER2/neu protein overexpression by IHC 
HER2/neu score  No. of the cases A percentage of the total number 
Score 0 44 9.8% 
Score + 1 71 15.8% 
Score + 2 306 68.3% 
Score + 3 27 6.0% 
 
 
CISH results for HER2/neu gene 
 amplification 
HER2/neu gene amplification was seen in 144 
(32.14%) specimens of the 448 studied cases. 
HER2/neu gene was not amplified in all cases (0%) of 
score 0 by IHC, while all the 27 cases (100%) with 
score +3 by IHC showed gene amplification by CISH, 
12(44.4%) cases showed low amplification and 15 
(55.5%) cases showed high amplification. Within 
cases of score + 1 by IHC, 15 (21.1%) cases show 
low gene amplification and no case show high 
amplification.  
Table 6: CISH results for HER2/neu gene amplification 
Ihc Results 
for 
HER2/neu 
Protein 
Over-
Expression 
Cish Results for HER2/neu Gene Amplification 
Total No. 
of cases 
Not 
ampli
fied 
Percen
tage 
(%) 
Low 
ampli
ficatio
n 
Percent
age (%) 
High 
amplifi
cation 
Percent
age (%) 
Equivo
cal 
Perce
ntage 
(%) 
Score 0 44 44 100% 0 0% 0 0% 0 0% 
Score +1 71 56 78.8% 15 21.1% 0 0% 0 0% 
Score +2 306 203 66.3% 79 25.8% 23 7.5% 1 0.3% 
Score +3 27 0 0% 12 44.4% 15 55.5% 0 0% 
 
 
Among equivocal positive cases of score + 2 
by IHC, 102 (33.3%) cases show HER2 gene 
amplification, 79 (25.8%) cases with low amplification 
and 23 (7.5%) cases with high amplification while one 
(0.3%) case was equivocal. As in Table 6 and Table 
7. 
Table 7: Percentage of positive cases for HER2/neu gene 
amplification by CISH within each score 
HER2/neu protein expression by 
IHC 
Percentage of positive cases for HER2/neu gene 
amplification by CISH within each score 
Negative score 0 0 % 
Negative score 1 21.1 % 
Equivocal positive score 2 33.3 % 
Positive score 3 100 % 
 
Relationship between HER2/neu and 
 Estrogen receptor 
HER2/neu gene amplification was present in 
70 (41.4%) cases of those with no estrogen receptor 
expression, while 75 (26.9%) cases of those 
expressing estrogen receptors showed no HER2/neu 
gene amplification. There is a significant negative 
relationship between HER2/neu status and ER 
expression with a p-value of 0.015. As shown in Table 
8. 
Table 8: Relationship between HER2/neu and Estrogen 
receptors 
Relationship between 
HER2/neu and 
Estrogen receptor 
CISH results 
P value 
Not amplified percentage Amplified percentage 
ER 
status 
No expression 99 58.6% 70 41.4% 
0.015 
expression 204 73.1% 75 26.9% 
 
 
Relationship between HER2 and 
 Progesterone receptor 
HER2/neu gene amplification was present in 
64 (44.4%) cases of those with no progesterone 
receptor expression, while 81 (26.6%) cases of those 
expressing progesterone receptors, showed no 
HER2/neu gene amplification.  
There is a significant negative relationship 
between HER2/neu status and PR expression with a 
p-value of 0.001. As shown in Table 9. 
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Table 9: Relationship between HER2 and Progesterone 
receptor 
Relationship between 
HER2/neu and 
Progesterone receptor 
CISH results 
P 
value Not amplified percentage Amplified percentage 
PR 
status 
No expression 80 55.5% 64 44.4% 
0.001 
expressed 223 73.3% 81 26.6% 
 
 
Relationship between HER2/neu and 
 patients age 
HER2/neu gene was amplified in 67 (36.4%) 
specimens from young patients (45 years and 
younger), and it was amplified in 78 (29.5%) 
specimens from old patients (more than 45 years) with 
no significant relationship between patient’s age and 
HER2/neu gene amplification. As shown in Table 10. 
Table 10: Relationship between HER2 and patients age 
Relationship between 
HER2/neu and patients 
age 
CISH results 
P 
value Not amplified percentage Amplified percentage 
Patients 
age 
≤ 45 years 117 63.6% 67 36.4% 
0.126 
> 45 years 186 70.5% 78 29.5% 
 
 
 
Discussion 
 
In Iraq, breast cancer is the most frequent 
cancer in females with 4824 cases were reported 
during 2015, with an annual incidence of 13.3 per 
100000 population [23]. 
Overexpression of human epidermal growth 
factor receptor type 2 (HER2/neu or ErbB-2), a 185-
kD receptor first described three decades ago, occurs 
in many tumours like 48.38% of endometrioid 
endometrial carcinoma and 20% to 30% of invasive 
breast carcinomas [24], [25]. Generally, patients with 
carcinomas that overexpress HER2/neu or that have a 
high copy number of its gene have worsened overall 
survival and might have different responses to a 
variety of hormonal and chemotherapeutic agents 
[26], [27], [28]. Thus, therapies aimed to target 
HER2/neu appear to be crucial in treating breast 
cancer. One such treatment is trastuzumab 
(Herceptin, Genentech), which is a humanised 
monoclonal antibody. Trastuzumab binds to an 
extracellular juxtamembrane domain of HER2/neu and 
inhibits proliferation and survival of HER2/neu-
dependent tumours. It has been approved by the 
Food and Drug Administration (FDA) for patients with 
invasive breast carcinoma with HER2/neu 
overexpression. The choice of a standard gold 
method for testing HER2/neu status had been an area 
of argument for a long time with controversy regarding 
the use of immunohistochemistry with the application 
of in situ hybridisation in equivocal cases or the use of 
in situ hybridisation from the start in all cases 
diagnosed with invasive breast carcinoma [13].  
In this study, IHC was done to ascertain the 
score of HER2/neu protein expression in tumour 
samples. About two thirds of the cases (306; 68.3%) 
were equivocally positive (2+ reactivity) whereas 115 
(25.6%) case were negative (0, 1+ reactivity) and 27 
(6.0%) cases were positive (3+ reactivity).  
a)
 
b) 
 
c)
 
d) 
 
Figure 2: a) HER2/neu high amplification by CISH in the equivocal 
case by IHC; b) HER2/neu low amplification by CISH in the 
equivocal case by IHC; c) HER2/neu equivocal by CISH in the 
equivocal case by IHC; d) HER2/neu non-amplification by CISH in 
the equivocal case by IHC 
 
These figures differ from that reported in other 
studies like Eswarachary V et al., that showed 
approximately a third of the cases (143/432, 33.10%) 
being positive (3+ reactivity) while 47 cases (10.88%) 
were negative (0, 1+ reactivity) with a substantial 
number of cases (242/432; 56.01%) showed 
equivocal positivity (2+ reactivity) [29]. In Varga Z et 
al., study, 12% of the cases were 3+ on IHC (184 of 
1522 cases), 26.5% of the cases were 2+ (404 of 
1522), and 61.4% of the cases were negative 0/1+ on 
IHC (934 of 1522) [30]. This may be attributed to 
sampling bias as most of the cases in this study were 
of score 2+ that are routinely submitted for in situ 
hybridisation to test the HER2/neu gene amplification. 
Expression of estrogen receptors was seen in 
279 (62.27%) cases in this study, and the expression 
of progesterone receptors was seen in 304 (67.85%) 
cases. This is in agreement with Eswarachary V et al., 
where approximately two thirds (284/432, 65.74%) of 
their cases were positive for ER receptor expression 
whereas 59.72% (258/432) of the cases were positive 
for PR receptor expression [29]. The same results 
were obtained by Alwan N et al., showing the 
registered rates of positive ER and PR tumour 
contents of 67.8% and 65.3% respectively [31]. 
Analysing the correlation between CISH 
HER2/neu status and ER/PR expression 
demonstrated that ER and PR expressions were 
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higher in HER2/neu negative tumours compared to 
HER2/neu positive tumours. These inverse 
associations between the expression of ER/PR and 
HER2/neu amplification were significant with p-value 
0.015(with ER) and p-value 0.001(with PR). This is 
similar to what was obtained by Eswarachary V et al., 
but with a still significant number of HER2/neu positive 
tumours, which also expressed ER/ PR [29]. The 
inverse relationship between ER/PR status and 
HER2/neu is logic in that HER2/neu hyper-functioning 
usually associates with high-grade aggressive 
tumours in contrary to ER and may explain the cause 
of poor responsiveness to tamoxifen therapy in a 
patient who express both ER and HER2/neu [29].
 
Regarding the correlation between age of the 
patient and HER2/neu status by CISH, there was no 
significant correlation between them with p-value 
0.126. This is in agreement with Barros et al., [32], 
while Jabbar N et al., found in their study significant 
correlation between female age and her HER2/neu 
amplification by CISH; where increased age was 
associated more with gene amplification [33]. 
HER2/neu gene amplification rates in different 
scores of HER2/neu protein expression by IHC in this 
study were as follow: 0% in score 0, 21.1% in score 
1+ (all were with low amplification), 33.3% in score 2+ 
(25.8% with low amplification and 7.5% with high 
amplification with one (0.3%) case equivocal) and 
100% in score3+. In a study done by Vocaturo et al., 
there was no case of 0/1+ by IHC score showed gene 
amplification by CISH, 53% of score 2+ showed gene 
amplification and 64% of cases with score 3+ were 
amplified by CISH [34]. In another study from Iraq 
done by Khashman B et al., for equivocally positive 
cases only, 24.5% (12 out of 49) showed low 
amplification results while 8.1% (4 out of 49) showed 
high amplification results with 32.6% overall 
percentage of CISH positive cases within score 2+ 
[35]. Manuelito A Madrid et al., in their study of 160 
cases of invasive breast carcinoma for HER2/neu 
status, 80 were IHC positive (score 2+ and 3+), and 
80 were IHC negative (score 0 and score 1+). With 
the CISH assay, 58 (36.25%) of their 160 cases 
showed HER2/neu gene amplification. No case (0%) 
of the negative ones show gene amplification by 
CISH, while all cases (100%) of score 3+ showed 
positive results with CISH, 9 (22.5%) cases with low 
amplification and 39 (97.5%) cases with high 
amplification, 18 cases (45%) of score 2+ were 
positive by CISH, 8 (20%) cases with low amplification 
and 10 (25%) cases with high amplification [36]. The 
subjectivity of the immunohistochemical method for 
assessment of HER2/neu expression lies behind this 
discrepancy in results between different studies. This 
may result from up scoring or down the scoring of the 
expression, so that cases with score 1+ may be 
reported by others as 2+ or underestimate score 3+ 
as 2+. For that reason, the American Society of 
Clinical Oncology (ASCO)/College of American 
Pathologists (CAP), human epidermal growth factor 
receptor 2 (HER2) testing Expert Panel aimed to 
improve the analytic validity of HER2/neu testing and 
the clinical utility of HER2/neu as a predictive 
biomarker for the potential responsiveness to 
therapies targeting the HER2/neu protein [37].
 
Eswarachary V et al., in their similar research, but with 
use of fluorescent in situ hybridisation (FISH) 
technique for HER2/neu gene status testing, 
HER2/neu was non-amplified in more than half of their 
cases (223/432, 51.6%) while it was amplified in 
46.3% cases (200/432). IHC was done to evaluate the 
expression of HER2/neu protein in tumour samples. 
Approximately one-third of the samples (143/432, 
33.1%) were positive (3+ reactivity), whereas 47 
samples (10.8%) were negative (0/1+ reactivity). Also, 
a substantial number of patients (242/432, 56%) 
showed equivocal 2+ reactivity. Of the equivocal IHC 
cases, 68 (28.10%) cases were amplified for 
HER2/neu by FISH, 168 (69.42%) cases were not 
amplified, and the rest (2.5%) were FISH equivocal. 
Within score 3+, 91.6% of the cases showed 
amplification by FISH and, within score 0/1+, only 
2.1% of the cases were positive [29]. 
 Study Limitations: The pre-analytical 
variables, including fixation time, environment and 
tissue processing, could be controlled because the 
significant number of samples was referred from other 
centres. 
In conclusion, although IHC is a widely used, 
less expensive and reliable test, we strongly advice 
performance of CISH in assessment of HER2/nu gene 
status in all cases diagnosed with breast carcinoma 
as significant number of cases that were reported as 
negative by IHC showed positive amplification by 
CISH and can get benefit from anti-HER2 targeted 
treatments. In addition to the subjectivity and the 
several limitations in the interpretation of the IHC test 
results. 
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